Swiss National Bank Acquires 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Swiss National Bank lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 38.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 68,600 shares of the company's stock after acquiring an additional 19,000 shares during the quarter. Swiss National Bank owned approximately 0.13% of Spyre Therapeutics worth $1,597,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC grew its holdings in shares of Spyre Therapeutics by 64.7% during the third quarter. Barclays PLC now owns 105,467 shares of the company's stock valued at $3,101,000 after buying an additional 41,424 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Spyre Therapeutics during the 4th quarter valued at about $290,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Spyre Therapeutics by 239.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company's stock valued at $9,802,000 after purchasing an additional 235,094 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Spyre Therapeutics in the fourth quarter worth approximately $6,241,000. Finally, Jane Street Group LLC increased its stake in Spyre Therapeutics by 78.7% in the 3rd quarter. Jane Street Group LLC now owns 20,641 shares of the company's stock valued at $607,000 after buying an additional 9,090 shares during the period. Institutional investors and hedge funds own 80.39% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on SYRE shares. Wolfe Research started coverage on Spyre Therapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 price objective for the company. The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Finally, Wedbush reaffirmed an "outperform" rating and set a $65.00 price objective on shares of Spyre Therapeutics in a research report on Monday, January 13th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Spyre Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $50.33.

Remove Ads

Spyre Therapeutics Stock Down 10.0 %

SYRE stock traded down $1.80 during mid-day trading on Monday, reaching $16.14. 740,827 shares of the stock traded hands, compared to its average volume of 556,890. The firm has a market capitalization of $972.55 million, a PE ratio of -2.16 and a beta of 2.98. The business has a 50-day moving average of $20.54 and a two-hundred day moving average of $25.55. Spyre Therapeutics, Inc. has a 52 week low of $16.14 and a 52 week high of $40.84.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.08. On average, equities research analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).